Bain Capital Public Equity Management II LLC Grows Stock Position in Haleon plc (NYSE:HLN)

Bain Capital Public Equity Management II LLC raised its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,844,010 shares of the company's stock after buying an additional 165,929 shares during the period. Haleon comprises approximately 1.2% of Bain Capital Public Equity Management II LLC's holdings, making the stock its 20th largest position. Bain Capital Public Equity Management II LLC owned approximately 0.06% of Haleon worth $27,132,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Addison Advisors LLC boosted its stake in shares of Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after acquiring an additional 1,106 shares during the last quarter. Synovus Financial Corp lifted its position in Haleon by 0.8% during the third quarter. Synovus Financial Corp now owns 148,834 shares of the company's stock valued at $1,575,000 after purchasing an additional 1,216 shares in the last quarter. Haverford Trust Co grew its holdings in Haleon by 5.0% during the fourth quarter. Haverford Trust Co now owns 25,842 shares of the company's stock valued at $247,000 after purchasing an additional 1,233 shares during the period. Bessemer Group Inc. increased its position in Haleon by 5.9% in the fourth quarter. Bessemer Group Inc. now owns 22,301 shares of the company's stock worth $212,000 after buying an additional 1,236 shares in the last quarter. Finally, United Capital Financial Advisors LLC increased its position in Haleon by 3.5% in the fourth quarter. United Capital Financial Advisors LLC now owns 37,475 shares of the company's stock worth $358,000 after buying an additional 1,266 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

HLN stock traded up $0.10 during mid-day trading on Wednesday, hitting $10.77. The company had a trading volume of 19,358,927 shares, compared to its average volume of 7,636,847. The company has a market capitalization of $48.57 billion, a price-to-earnings ratio of 31.66, a P/E/G ratio of 2.82 and a beta of 0.24. The company has a 50-day moving average price of $10.20 and a 200 day moving average price of $9.83. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $8.12 and a 12-month high of $10.85.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. On average, research analysts anticipate that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's dividend payout ratio (DPR) is 58.97%.

Analyst Ratings Changes

Several research firms recently issued reports on HLN. HSBC reissued a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Finally, Barclays reiterated an "overweight" rating on shares of Haleon in a research report on Tuesday. Six analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.